Fresenius Medical Care AG & Co. KGaA (ETR:FME) received a €90.00 ($107.14) price target from analysts at Morgan Stanley in a note issued to investors on Friday. The firm presently has a “buy” rating on the stock.

Several other research firms have also weighed in on FME. Goldman Sachs Group, Inc. (The) set a €100.00 ($119.05) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Friday, June 30th. Jefferies Group LLC set a €85.00 ($101.19) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Friday, June 16th. J P Morgan Chase & Co set a €106.40 ($126.67) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Tuesday, June 13th. Oddo Securities set a €95.00 ($113.10) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Monday, June 12th. Finally, Independent Research GmbH set a €90.00 ($107.14) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company’s stock. Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Hold” and a consensus target price of €88.39 ($105.22).

Fresenius Medical Care AG & Co. KGaA (FME) opened at 81.496 on Friday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of €70.82 and a 12-month high of €89.07. The firm has a market capitalization of €25.01 billion and a price-to-earnings ratio of 21.015. The company’s 50-day moving average price is €79.19 and its 200-day moving average price is €81.57.

COPYRIGHT VIOLATION WARNING: “Fresenius Medical Care AG & Co. KGaA (FME) Given a €90.00 Price Target by Morgan Stanley Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/15/fresenius-medical-care-ag-90-00-price-target-by-morgan-stanley-analysts.html.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.